Comparison of Dabigatran Versus Warfarin Treatment for Prevention of New Cerebral Lesions in Valvular Atrial Fibrillation.

[1]  Jeroen J. Bax,et al.  2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). , 2020, European heart journal.

[2]  K. Aizawa,et al.  Risk factors and localization of silent cerebral infarction in patients with atrial fibrillation. , 2019, Heart rhythm.

[3]  J. Myong,et al.  Outcomes of Direct Oral Anticoagulants in Patients With Mitral Stenosis. , 2019, Journal of the American College of Cardiology.

[4]  H. May,et al.  Atrial Fibrillation and Dementia: Exploring the Association, Defining Risks and Improving Outcomes , 2018, Arrhythmia & electrophysiology review.

[5]  A. Camm,et al.  The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. , 2018, European heart journal.

[6]  L. Fleisher,et al.  2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2017, Journal of the American College of Cardiology.

[7]  Eric E. Smith,et al.  Prevention of Stroke in Patients With Silent Cerebrovascular Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2017, Stroke.

[8]  S. Yusuf,et al.  Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart DiseaseClinical Perspective , 2016 .

[9]  Eric E. Smith,et al.  2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials , 2015, Journal of Nuclear Cardiology.

[10]  R. de Caterina,et al.  Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial , 2015, Circulation.

[11]  Y. Miki,et al.  Predictors of silent brain infarction on magnetic resonance imaging in patients with nonvalvular atrial fibrillation: A transesophageal echocardiographic study. , 2015, American heart journal.

[12]  N. Hasebe,et al.  Non-vitamin k antagonist oral anticoagulants do not increase cerebral microbleeds. , 2015, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[13]  S. Kalantarian,et al.  Association Between Atrial Fibrillation and Silent Cerebral Infarctions , 2014, Annals of Internal Medicine.

[14]  R. McBane,et al.  Distribution of thromboembolism in valvular versus non-valvular atrial fibrillation , 2014, Expert review of cardiovascular therapy.

[15]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[16]  S. Connolly,et al.  Dabigatran versus warfarin in patients with mechanical heart valves. , 2013, The New England journal of medicine.

[17]  D. Atar,et al.  Mass screening for silent atrial fibrillation in high risk patients - preliminary results from the STROKESTOP trial , 2013 .

[18]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[19]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[20]  Seung-Hoon Lee,et al.  Silent Microbleeds and Hemorrhagic Conversion of an Embolic Infarction , 2007, Journal of clinical neurology.

[21]  A. Salvador,et al.  Effect of antithrombotic therapy in patients with mitral stenosis and atrial fibrillation: a sub-analysis of NASPEAF randomized trial. , 2006, European heart journal.

[22]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.

[23]  A. Salvador,et al.  Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. , 2004, Journal of the American College of Cardiology.

[24]  J C Froment,et al.  Old Microbleeds Are a Potential Risk Factor for Cerebral Bleeding After Ischemic Stroke: A Gradient-Echo T2*-Weighted Brain MRI Study , 2002, Stroke.

[25]  A. R. Twardock,et al.  Thrombogenicity of polyethylene oxide-bonded Dacron sewing ring in a mechanical heart valve. , 1999, The Journal of heart valve disease.

[26]  Y. Ko,et al.  Predictors of Systemic Embolism in Patients with Mitral Stenosis: A Prospective Study , 1998, Annals of Internal Medicine.

[27]  L. Wilkins.  Silent brain infarction in nonrheumatic atrial fibrillation , 1996, Neurology.

[28]  P. Wolf,et al.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.

[29]  A. Selzer,et al.  Natural History of Mitral Stenosis: A Review , 1972, Circulation.